Skip to main navigation
Contact Us
Careers
facebook
instagram
linkedin
Our Company
Who We Are
Leadership & Board
Patient Advocacy
Diversity, Equity, Inclusion & Belonging
Grant Programs
ISR Grants
Med Ed Grants
Contact Us
Careers
News
Our Science
Our Pipeline
Sparsentan for IgAN
Sparsentan for FSGS
Pegtibatinase
Alagille Syndrome Collaboration
Therapeutic Areas
IgA Nephropathy (IgAN)
Focal Segmental Glomerulosclerosis (FSGS)
Classical Homocystinuria (HCU)
Alagille Syndrome (ALGS)
Cystinuria
Clinical Trials
Expanded Access
Publications
Medical Affairs
Our Therapies
Rare Life
Investors & Media
Press Releases
Events & Presentations
Financials
SEC Filings
Quarterly Results
Stock Information
Stock Quote & Chart
Historic Stock Lookup
Analyst Coverage
Corporate Governance
Corporate Governance Documents
Leadership & Board
Shareholder Services
Investor Q&A
Contact Us
Email Alerts
EVENT
DETAILS
Home
▶
Investors & Media
▶
Travere Therapeutics Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
«
Back
Travere Therapeutics Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
Feb 24, 2022 at 4:30 PM EST
Listen to webcast
Print Page
Email Alerts
Download Library
RSS Feeds
Share
Search